Moreover, when CD4+ T cells from SPMS patients, and even RRMS patients, were activated with anti-CD3+ rIL-2, they demonstrated an inability to exhibit normal surface CTLA-4 expression [31]. This evidence concerns the gene CD4 and secondary progressive multiple sclerosis.